Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) EBT (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of EBT data on record, last reported at -$34.3 million in Q4 2022.

  • For Q4 2022, EBT fell 128.3% year-over-year to -$34.3 million; the TTM value through Dec 2022 reached -$119.5 million, down 186.22%, while the annual FY2025 figure was -$164.5 million, 1.76% up from the prior year.
  • EBT reached -$34.3 million in Q4 2022 per AVIR's latest filing, down from -$11.9 million in the prior quarter.
  • Across five years, EBT topped out at $121.2 million in Q4 2021 and bottomed at -$42.1 million in Q1 2022.
  • Average EBT over 3 years is $678666.7, with a median of -$10.9 million recorded in 2020.
  • Peak YoY movement for EBT: surged 870.14% in 2021, then plummeted 457.19% in 2022.
  • A 3-year view of EBT shows it stood at $20.7 million in 2020, then skyrocketed by 486.91% to $121.2 million in 2021, then crashed by 128.3% to -$34.3 million in 2022.
  • Per Business Quant database, its latest 3 readings for EBT were -$34.3 million in Q4 2022, -$11.9 million in Q3 2022, and -$31.2 million in Q2 2022.